James Anthony McCaul
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
James Anthony McCaul has a total of 278 co-authors. Here are the top co-authors by number of shared publications:
- Hisham Mehanna
Institute of Head and Neck Studies and Education, University of Birmingham, B15 2TT, UK
17 shared publications - Paul Nankivell
Department of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK
17 shared publications - Andrew Graeme Schache
Liverpool Head & Neck Centre Liverpool University Hospitals NHS Foundation Trust, Aintree University Hospital Liverpool UK
16 shared publications - Max Robinson
Department of Cellular Pathology Newcastle upon Tyne Hospitals NHS Foundation Trust Newcastle Upon Tyne UK
16 shared publications - Stuart Charles Winter
Nuffield Department of Surgical Sciences University of Oxford Oxford UK
16 shared publications - Alice Sitch
Institute of Applied Health Research, University of Birmingham, Birmingham, UK
15 shared publications
Latest Publications
- 14 June 2025
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 117 (11) , 2202-2218
Multidisciplinary evidence-based consensus statements on salvage surgery for recurrent head and neck cancer (International Centre for Recurrent Head and Neck Cancer)
Background: Recurrent head and neck squamous cell carcinomas are an understudied subgroup, lacking high-quality evidence and thus gold standard management recommendations, resulting in major variations in practice. The aim of this project was to deliver a national multidisciplinary expert consensus on patients with recurrent head and neck squamous cell carcinoma managed by curative salvage surgery. Methods: The Appraisal of Guidelines for Research and Evaluation II (AGREEII) protocol guided the Delphi process. Best practice statements were developed after literature review on the perioperative management and surgical salvage of major recurrent head and neck squamous cell carcinoma subsites. Members of the International Centre for Recurrent Head and Neck Cancer network and other UK-based professional stakeholder organizations were invited into an online Delphi study. Participants voted on statements over 3 rounds, with items modified in response to vote thresholds and comments. Results: A total of 28 experts participated, including 11 otolaryngologists, 7 oncologists, 9 oral and maxillofacial surgeons, and 1 speech and language therapist. Consensus was achieved on 73 statements, with 29 (39.7%) achieving unanimous (threshold = 100%) and 25 (34.2%) very strongly supported (threshold > 90%) agreement. Conclusions: Salvage surgeries for recurrent head and neck squamous cell carcinoma are challenging cases that require intensive multidisciplinary input to achieve cure while balancing impact on function and quality of life. In this article, we provide a large series of statements based on UK-wide expert consensus that will guide clinicians through the complex intra- and perioperative management of patients undergoing surgical salvage.
- 14 June 2025
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 117 (11) , 2202-2218
Multidisciplinary evidence-based consensus statements on salvage surgery for recurrent head and neck cancer (International Centre for Recurrent Head and Neck Cancer)
Background: Recurrent head and neck squamous cell carcinomas are an understudied subgroup, lacking high-quality evidence and thus gold standard management recommendations, resulting in major variations in practice. The aim of this project was to deliver a national multidisciplinary expert consensus on patients with recurrent head and neck squamous cell carcinoma managed by curative salvage surgery. Methods: The Appraisal of Guidelines for Research and Evaluation II (AGREEII) protocol guided the Delphi process. Best practice statements were developed after literature review on the perioperative management and surgical salvage of major recurrent head and neck squamous cell carcinoma subsites. Members of the International Centre for Recurrent Head and Neck Cancer network and other UK-based professional stakeholder organizations were invited into an online Delphi study. Participants voted on statements over 3 rounds, with items modified in response to vote thresholds and comments. Results: A total of 28 experts participated, including 11 otolaryngologists, 7 oncologists, 9 oral and maxillofacial surgeons, and 1 speech and language therapist. Consensus was achieved on 73 statements, with 29 (39.7%) achieving unanimous (threshold = 100%) and 25 (34.2%) very strongly supported (threshold > 90%) agreement. Conclusions: Salvage surgeries for recurrent head and neck squamous cell carcinoma are challenging cases that require intensive multidisciplinary input to achieve cure while balancing impact on function and quality of life. In this article, we provide a large series of statements based on UK-wide expert consensus that will guide clinicians through the complex intra- and perioperative management of patients undergoing surgical salvage.
- Open Access
- 17 January 2024
- Published by American Association for Cancer Research (AACR)
Figure 2 from Developing and Validating a Multivariable Prognostic-Predictive Classifier for Treatment Escalation of Oropharyngeal Squamous Cell Carcinoma: The PREDICTR-OPC Study
A, Heatmaps summarizing the molecular and clinical data from training and validation sets. Rows contain clinical covariates and molecular biomarkers, while columns contain patients. Protein abundance H-scores (range: 0–300) were divided by 30 and Z transformed (μ = 0, σ = 1) for training and validation sets separately. Column order in each of the training and validation sets was determined by first sorting (low to high Z-score) on the protein biomarkers one by one (bottom up) and then OS event. B, Box plots displaying range of fitted coefficients including 25th percentile (Q1), median, and 75th percentile (Q3). To test the stability of the variables selected in the multivariable model, bootstrapping was performed on the training cohort (1,000 times) and Cox proportional hazards model was fitted with backward elimination on each subset. For each bootstrap iteration, coefficients of the resulting variables selected by the model are displayed in the box plots alongside their % frequency of inclusion over 1,000 iterations. Bootstrapping results confirmed the relative importance of variables in our original model (Supplementary Table S6), as these were ranked among the top recurrently selected variables over 1,000 iterations. Upper whisker of the box plots indicates: min (max(x), Q3 + 1.5 × IQR) and lower whisker indicates: max (min(x), Q1–1.5 × IQR) where IQR = Q3−Q1. Color key: TILS-3 = high, TILS-2 = moderate, TILS-1 = low.
- 17 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 2 from Developing and Validating a Multivariable Prognostic-Predictive Classifier for Treatment Escalation of Oropharyngeal Squamous Cell Carcinoma: The PREDICTR-OPC Study
A, Heatmaps summarizing the molecular and clinical data from training and validation sets. Rows contain clinical covariates and molecular biomarkers, while columns contain patients. Protein abundance H-scores (range: 0–300) were divided by 30 and Z transformed (μ = 0, σ = 1) for training and validation sets separately. Column order in each of the training and validation sets was determined by first sorting (low to high Z-score) on the protein biomarkers one by one (bottom up) and then OS event. B, Box plots displaying range of fitted coefficients including 25th percentile (Q1), median, and 75th percentile (Q3). To test the stability of the variables selected in the multivariable model, bootstrapping was performed on the training cohort (1,000 times) and Cox proportional hazards model was fitted with backward elimination on each subset. For each bootstrap iteration, coefficients of the resulting variables selected by the model are displayed in the box plots alongside their % frequency of inclusion over 1,000 iterations. Bootstrapping results confirmed the relative importance of variables in our original model (Supplementary Table S6), as these were ranked among the top recurrently selected variables over 1,000 iterations. Upper whisker of the box plots indicates: min (max(x), Q3 + 1.5 × IQR) and lower whisker indicates: max (min(x), Q1–1.5 × IQR) where IQR = Q3−Q1. Color key: TILS-3 = high, TILS-2 = moderate, TILS-1 = low.
- Open Access
- 17 January 2024
- Published by American Association for Cancer Research (AACR)
Figure 3 from Developing and Validating a Multivariable Prognostic-Predictive Classifier for Treatment Escalation of Oropharyngeal Squamous Cell Carcinoma: The PREDICTR-OPC Study
A–C, Prognostic and predictive assessment of risk groups predicted by multivariable survival model (trained with backward elimination using AIC) based on molecular biomarkers only with OS, when applied to the training cohort. D–F, Prognostic and predictive assessment of risk groups predicted by the molecular biomarkers only multivariable model, when applied to the validation cohort. Risk groups in the validation cohort were created using the thresholds (two-group classification: median risk score; three-group classification: tertiles of risk score) derived from the training set. Color key A, D: black = low-risk group, red = high-risk group; B, E: black = low-risk, red = intermediate (Int.)-risk, Blue=high-risk group; C, F: Red = low-risk surgery, black = low-risk no surgery, pink = high-risk surgery, blue = high-risk no surgery group. Models were adjusted for clinical covariates: T-category, N-category, smoking status, age, radiotherapy, and chemotherapy.
- 17 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 3 from Developing and Validating a Multivariable Prognostic-Predictive Classifier for Treatment Escalation of Oropharyngeal Squamous Cell Carcinoma: The PREDICTR-OPC Study
A–C, Prognostic and predictive assessment of risk groups predicted by multivariable survival model (trained with backward elimination using AIC) based on molecular biomarkers only with OS, when applied to the training cohort. D–F, Prognostic and predictive assessment of risk groups predicted by the molecular biomarkers only multivariable model, when applied to the validation cohort. Risk groups in the validation cohort were created using the thresholds (two-group classification: median risk score; three-group classification: tertiles of risk score) derived from the training set. Color key A, D: black = low-risk group, red = high-risk group; B, E: black = low-risk, red = intermediate (Int.)-risk, Blue=high-risk group; C, F: Red = low-risk surgery, black = low-risk no surgery, pink = high-risk surgery, blue = high-risk no surgery group. Models were adjusted for clinical covariates: T-category, N-category, smoking status, age, radiotherapy, and chemotherapy.
- Open Access
- 17 January 2024
- Published by American Association for Cancer Research (AACR)
Figure 2 from Developing and Validating a Multivariable Prognostic-Predictive Classifier for Treatment Escalation of Oropharyngeal Squamous Cell Carcinoma: The PREDICTR-OPC Study
A, Heatmaps summarizing the molecular and clinical data from training and validation sets. Rows contain clinical covariates and molecular biomarkers, while columns contain patients. Protein abundance H-scores (range: 0–300) were divided by 30 and Z transformed (μ = 0, σ = 1) for training and validation sets separately. Column order in each of the training and validation sets was determined by first sorting (low to high Z-score) on the protein biomarkers one by one (bottom up) and then OS event. B, Box plots displaying range of fitted coefficients including 25th percentile (Q1), median, and 75th percentile (Q3). To test the stability of the variables selected in the multivariable model, bootstrapping was performed on the training cohort (1,000 times) and Cox proportional hazards model was fitted with backward elimination on each subset. For each bootstrap iteration, coefficients of the resulting variables selected by the model are displayed in the box plots alongside their % frequency of inclusion over 1,000 iterations. Bootstrapping results confirmed the relative importance of variables in our original model (Supplementary Table S6), as these were ranked among the top recurrently selected variables over 1,000 iterations. Upper whisker of the box plots indicates: min (max(x), Q3 + 1.5 × IQR) and lower whisker indicates: max (min(x), Q1–1.5 × IQR) where IQR = Q3−Q1. Color key: TILS-3 = high, TILS-2 = moderate, TILS-1 = low.
- 17 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 2 from Developing and Validating a Multivariable Prognostic-Predictive Classifier for Treatment Escalation of Oropharyngeal Squamous Cell Carcinoma: The PREDICTR-OPC Study
A, Heatmaps summarizing the molecular and clinical data from training and validation sets. Rows contain clinical covariates and molecular biomarkers, while columns contain patients. Protein abundance H-scores (range: 0–300) were divided by 30 and Z transformed (μ = 0, σ = 1) for training and validation sets separately. Column order in each of the training and validation sets was determined by first sorting (low to high Z-score) on the protein biomarkers one by one (bottom up) and then OS event. B, Box plots displaying range of fitted coefficients including 25th percentile (Q1), median, and 75th percentile (Q3). To test the stability of the variables selected in the multivariable model, bootstrapping was performed on the training cohort (1,000 times) and Cox proportional hazards model was fitted with backward elimination on each subset. For each bootstrap iteration, coefficients of the resulting variables selected by the model are displayed in the box plots alongside their % frequency of inclusion over 1,000 iterations. Bootstrapping results confirmed the relative importance of variables in our original model (Supplementary Table S6), as these were ranked among the top recurrently selected variables over 1,000 iterations. Upper whisker of the box plots indicates: min (max(x), Q3 + 1.5 × IQR) and lower whisker indicates: max (min(x), Q1–1.5 × IQR) where IQR = Q3−Q1. Color key: TILS-3 = high, TILS-2 = moderate, TILS-1 = low.
- Open Access
- 17 January 2024
- Published by American Association for Cancer Research (AACR)
Figure 1 from Developing and Validating a Multivariable Prognostic-Predictive Classifier for Treatment Escalation of Oropharyngeal Squamous Cell Carcinoma: The PREDICTR-OPC Study
Photomicrographs showing examples of the biomarkers in the predictive classifier: p16 immunohistochemistry (A–C), high-risk HPV in situ hybridization (D–F), survivin immunohistochemistry (G–I), and TILs (J–L). A, p16-positive tumor showing strong and diffuse nuclear and cytoplasmic staining. B, p16-negative tumor showing weak and diffuse cytoplasmic staining. C, p16-negative tumor with no staining. D–E, High-risk HPV-positive tumors showing diffuse nuclear and cytoplasmic staining (D) and punctate nuclear staining (E). F, High-risk HPV-negative tumor with no staining. G–I, Survivin staining showing tumors with high (G), medium (H), and low (I) H-scores. J–L, Cases with high (J), moderate (K), and low (L) TILs.
- 17 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 1 from Developing and Validating a Multivariable Prognostic-Predictive Classifier for Treatment Escalation of Oropharyngeal Squamous Cell Carcinoma: The PREDICTR-OPC Study
Photomicrographs showing examples of the biomarkers in the predictive classifier: p16 immunohistochemistry (A–C), high-risk HPV in situ hybridization (D–F), survivin immunohistochemistry (G–I), and TILs (J–L). A, p16-positive tumor showing strong and diffuse nuclear and cytoplasmic staining. B, p16-negative tumor showing weak and diffuse cytoplasmic staining. C, p16-negative tumor with no staining. D–E, High-risk HPV-positive tumors showing diffuse nuclear and cytoplasmic staining (D) and punctate nuclear staining (E). F, High-risk HPV-negative tumor with no staining. G–I, Survivin staining showing tumors with high (G), medium (H), and low (I) H-scores. J–L, Cases with high (J), moderate (K), and low (L) TILs.
- Open Access
- 17 January 2024
- Published by American Association for Cancer Research (AACR)
Figure 1 from Developing and Validating a Multivariable Prognostic-Predictive Classifier for Treatment Escalation of Oropharyngeal Squamous Cell Carcinoma: The PREDICTR-OPC Study
Photomicrographs showing examples of the biomarkers in the predictive classifier: p16 immunohistochemistry (A–C), high-risk HPV in situ hybridization (D–F), survivin immunohistochemistry (G–I), and TILs (J–L). A, p16-positive tumor showing strong and diffuse nuclear and cytoplasmic staining. B, p16-negative tumor showing weak and diffuse cytoplasmic staining. C, p16-negative tumor with no staining. D–E, High-risk HPV-positive tumors showing diffuse nuclear and cytoplasmic staining (D) and punctate nuclear staining (E). F, High-risk HPV-negative tumor with no staining. G–I, Survivin staining showing tumors with high (G), medium (H), and low (I) H-scores. J–L, Cases with high (J), moderate (K), and low (L) TILs.
- 17 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 1 from Developing and Validating a Multivariable Prognostic-Predictive Classifier for Treatment Escalation of Oropharyngeal Squamous Cell Carcinoma: The PREDICTR-OPC Study
Photomicrographs showing examples of the biomarkers in the predictive classifier: p16 immunohistochemistry (A–C), high-risk HPV in situ hybridization (D–F), survivin immunohistochemistry (G–I), and TILs (J–L). A, p16-positive tumor showing strong and diffuse nuclear and cytoplasmic staining. B, p16-negative tumor showing weak and diffuse cytoplasmic staining. C, p16-negative tumor with no staining. D–E, High-risk HPV-positive tumors showing diffuse nuclear and cytoplasmic staining (D) and punctate nuclear staining (E). F, High-risk HPV-negative tumor with no staining. G–I, Survivin staining showing tumors with high (G), medium (H), and low (I) H-scores. J–L, Cases with high (J), moderate (K), and low (L) TILs.
- Open Access
- 17 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Data 1 from Developing and Validating a Multivariable Prognostic-Predictive Classifier for Treatment Escalation of Oropharyngeal Squamous Cell Carcinoma: The PREDICTR-OPC Study
Combined Supplementary Methods, Figures and Tables
- 17 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data 1 from Developing and Validating a Multivariable Prognostic-Predictive Classifier for Treatment Escalation of Oropharyngeal Squamous Cell Carcinoma: The PREDICTR-OPC Study
Combined Supplementary Methods, Figures and Tables
- Open Access
- 17 January 2024
- Published by American Association for Cancer Research (AACR)
Figure 4 from Developing and Validating a Multivariable Prognostic-Predictive Classifier for Treatment Escalation of Oropharyngeal Squamous Cell Carcinoma: The PREDICTR-OPC Study
Multivariable survival modelling (trained with backward elimination using AIC) for composite (molecular biomarkers + clinical factors) and clinical factors only with OS. A–D, Assessment of composite and clinical only models in the validation cohort split into two and three risk groups. E–H, Assessment of composite and clinical only models’ predicted risk groups (low- and high-risk) stratified by surgery in the training (E and F) and validation cohorts (G and H). Risk groups in the validation cohort were created using the thresholds (two-group classification: median; three-group classification: tertiles) derived from the training set. In E, the estimate of HR (95% CI) was not possible due to absence of events in low, surgery+ group. Color key: same as Fig. 3.
- 17 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 4 from Developing and Validating a Multivariable Prognostic-Predictive Classifier for Treatment Escalation of Oropharyngeal Squamous Cell Carcinoma: The PREDICTR-OPC Study
Multivariable survival modelling (trained with backward elimination using AIC) for composite (molecular biomarkers + clinical factors) and clinical factors only with OS. A–D, Assessment of composite and clinical only models in the validation cohort split into two and three risk groups. E–H, Assessment of composite and clinical only models’ predicted risk groups (low- and high-risk) stratified by surgery in the training (E and F) and validation cohorts (G and H). Risk groups in the validation cohort were created using the thresholds (two-group classification: median; three-group classification: tertiles) derived from the training set. In E, the estimate of HR (95% CI) was not possible due to absence of events in low, surgery+ group. Color key: same as Fig. 3.
- Open Access
- 17 January 2024
- Published by American Association for Cancer Research (AACR)
Table 2 from Developing and Validating a Multivariable Prognostic-Predictive Classifier for Treatment Escalation of Oropharyngeal Squamous Cell Carcinoma: The PREDICTR-OPC Study
Clinical examples of the OS model.
- 17 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessTable 2 from Developing and Validating a Multivariable Prognostic-Predictive Classifier for Treatment Escalation of Oropharyngeal Squamous Cell Carcinoma: The PREDICTR-OPC Study
Clinical examples of the OS model.
- Open Access
- 17 January 2024
- Published by American Association for Cancer Research (AACR)
Table 1 from Developing and Validating a Multivariable Prognostic-Predictive Classifier for Treatment Escalation of Oropharyngeal Squamous Cell Carcinoma: The PREDICTR-OPC Study
Characteristics of the training and validation cohorts.
- 17 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessTable 1 from Developing and Validating a Multivariable Prognostic-Predictive Classifier for Treatment Escalation of Oropharyngeal Squamous Cell Carcinoma: The PREDICTR-OPC Study
Characteristics of the training and validation cohorts.